Central Venous Access and the Risk for Thromboembolic Events in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer

被引:4
|
作者
Rydell, Harriet [1 ]
Huge, Ylva [2 ]
Eriksson, Victoria [1 ]
Johansson, Markus [1 ]
Alamdari, Farhood [3 ]
Svensson, Johan [4 ]
Aljabery, Firas [2 ]
Sherif, Amir [1 ,2 ]
机构
[1] Umea Univ, Dept Surg & Perioperat Sci Urol & Androl, S-90187 Umea, Sweden
[2] Linkoping Univ, Div Urol, Dept Clin & Expt Med, S-58183 Linkoping, Sweden
[3] Vastmanland Hosp, Dept Urol, S-72189 Vasteras, Sweden
[4] Umea Univ, Umea Sch Business Econ & Stat USBE, Dept Stat, S-90187 Umea, Sweden
来源
LIFE-BASEL | 2022年 / 12卷 / 08期
基金
瑞典研究理事会;
关键词
complications; cystectomy; central venous catheters; neoadjuvant therapy; thromboembolism; urinary bladder neoplasms; UROTHELIAL CARCINOMA; CATHETERS; SAFE; CARE;
D O I
10.3390/life12081198
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Thromboembolic events (TEE) are high-risk complications in patients undergoing neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) for urothelial muscle-invasive bladder cancer (MIBC). The purpose of the study was to investigate any differences in TEE-incidence, comparing peripherally inserted central catheter (PICC) versus a totally implanted port (PORT) as CVA (central venous access) during NAC. We identified 947 cystectomized MIBC-patients from four Swedish medical centers in 2009-2021. Inclusion criteria were cT2-T4aN0M0 and 375 patients were finally eligible and evaluated, divided into: NAC-administered (n = 283) resp. NAC-naive-NAC-eligible (n = 92), the latter as tentative control group. Data on TEEs and types of CVA were retrospectively collected and individually validated, from final transurethral resection of the bladder tumor (TUR-B) to 30 days post-RC. Adjusted logistic regression and log rank test were used for statistical analyses. Amongst NAC-administered, 83% (n = 235) received PICCs and 15% (n = 42) PORTs. Preoperative TEEs occurred in 38 PICC-patients (16.2%) and in one PORT-patient (2.4%), with 47 individual events registered. We found a significantly increased odds ratio of TEE in NAC-administered PICC-patients compared to in PORT-patients (OR: 8.140, p-value: 0.042, 95% CI 1.078-61.455). Our findings indicate a greater risk for pre-RC TEEs with PICCs than with PORTs, suggesting favoring the usage of PORTs for MIBC-NAC-patients.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Delays in radical cystectomy for muscle-invasive bladder cancer
    Chu, Alice T.
    Holt, Sarah K.
    Wright, Jonathan L.
    Ramos, Jorge D.
    Grivas, Petros
    Yu, Evan Y.
    Gore, John L.
    [J]. CANCER, 2019, 125 (12) : 2011 - 2017
  • [32] A phase II study of neoadjuvant erlotinib (Tarceva) in patients with muscle-invasive bladder cancer undergoing radical cystectomy: Preliminary results
    Smith, Angela
    Coward, Matthew
    Kim, William
    Nielsen, Matthew
    Wallen, Eric
    Pruthi, Raj S.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2009, 209 (03) : S129 - S129
  • [33] A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results
    Pruthi, Raj S.
    Nielsen, Matthew
    Heathcote, Samuel
    Wallen, Eric M.
    Rathmell, W. Kim
    Godley, Paul
    Whang, Young
    Fielding, Julia
    Schultz, Heather
    Grigson, Gayle
    Smith, Angela
    Kim, William
    O'Donnell, Peter H.
    [J]. BJU INTERNATIONAL, 2010, 106 (03) : 349 - 356
  • [34] Phase II trial of neoadjuvant nivolumab with cisplatin and gemcitabine in muscle-invasive bladder cancer patients undergoing radical cystectomy.
    Gupta, Shilpa
    Agarwal, Neeraj
    Konety, Badrinath R.
    Weight, Christopher J.
    Thyagarajan, Bharat
    Murugan, Paari J.
    Koopmeiners, Joseph S.
    Sonpavde, Guru
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [35] A phase II study of neoadjuvant erlotinib (tarceva) in patients with muscle-invasive bladder cancer undergoing radical cystectomy: Preliminary results
    Pearson, Matthew
    Nix, Jeffrey
    Kim, William
    Grigson, Gayle
    Wallen, Eric
    Pruthi, Raj S.
    [J]. JOURNAL OF UROLOGY, 2008, 179 (04): : 119 - 119
  • [36] Thromboembolic events associated with neoadjuvant chemotherapy for muscle invasive cancer of the bladder.
    Qureshi, Muneeb
    Rehan, Ahmed
    Mok, Wai Kit
    Salawu, Abdulazeez
    Goktas Aydin, Sabin
    Tay, Jessica
    Hubbard, Rachel
    Catto, James W. F.
    Hussain, Syed A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL)
  • [37] Survival after sequential neoadjuvant chemotherapy followed by trimodal treatment or radical cystectomy for muscle-invasive bladder cancer
    Pierre-Louis Reignier
    Hélène Gauthier
    Christophe Hennequin
    Quiterie Aussedat
    Evanguelos Xylinas
    François Desgrandchamps
    Stéphane Culine
    Alexandra Masson-Lecomte
    Clément Dumont
    [J]. World Journal of Urology, 2023, 41 : 3249 - 3255
  • [38] PROGNOSTIC SIGNIFICANCE OF LYMPH NODE YIELD AT RADICAL CYSTECTOMY AFTER NEOADJUVANT CHEMOTHERAPY FOR MUSCLE-INVASIVE BLADDER CANCER
    Chelluri, Raju
    Xia, Leilei
    Taylor, Benjamin
    Guzzo, Thomas
    [J]. JOURNAL OF UROLOGY, 2018, 199 (04): : E1043 - E1044
  • [39] Neoadjuvant Chemotherapy Before Radical Cystectomy for Muscle-Invasive Bladder Cancer: Elective and Eligibility Factors Impacting Utilization
    Patel, Hiten D.
    Naha, Ushasi
    Chen, Victor S.
    Ko, Caitlyn
    Yang, Rachel
    Druck, Aleksander
    Rac, Goran
    Ellis, Jeffrey L.
    Gupta, Gopal N.
    Woods, Michael E.
    Gorbonos, Alex
    Flanigan, Robert
    Quek, Marcus L.
    [J]. UROLOGY PRACTICE, 2024, 11 (01) : 136 - 144
  • [40] Delaying Radical Cystectomy After Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer is Associated with Adverse Survival Outcomes
    Boeri, Luca
    Soligo, Matteo
    Frank, Igor
    Boorjian, Stephen A.
    Thompson, R. Houston
    Tollefson, Matthew
    Quevedo, Fernando J.
    Cheville, John C.
    Karnes, R. Jeffrey
    [J]. EUROPEAN UROLOGY ONCOLOGY, 2019, 2 (04): : 390 - 396